Abstract
There is strong evidence from observational studies suggesting serum C-reactive protein (CRP) is associated with cardiovascular and all-cause mortality. However, less is known about whether there are differences in the association of CRP with all-cause or cause specific mortality by sex, smoking, body mass index (BMI), or physical activity. We aimed to investigate these interactions and also investigate and compare the association of CRP and other inflammation markers (i.e., fibrinogen and leukocyte count) with all-cause and cause-specific mortality. Men and women aged 40–79 were recruited in 1993–1997 in the EPIC-Norfolk cohort study. A total of 16,850 participants with high-sensitivity assayed CRP data who had no known cancer, myocardial infarction and stroke at baseline were entered in the analysis to test the association of CRP, fibrinogen and leukocyte count with risk of all-cause and cause specific mortality. A total of, 2,603 all-cause deaths (1,452 in men) including 823 cardiovascular and 1,035 cancer deaths, were observed after 231,000 person-years of follow-up (median 14.3 years). CRP was positively associated with risk of all-cause, cardiovascular, and non-cancer non-cardiovascular mortality independent of established risk factors. The hazard ratio of all-cause mortality (95 % CI) for participants with CRP in the range of 3–10 and >10 mg/l (vs. <0.5 mg/l) was 1.56 (1.26–1.93) and 1.87 (1.43–2.43) respectively in men and 1.34 (1.07–1.68) and 1.98 (1.50–2.63) in women. The association was less positively graded in women with the increased risk being significant only at higher levels of the CRP distribution. The association persisted in never smokers and did not vary by levels of BMI or physical activity. Although fibrinogen and leukocyte count were also positively associated with mortality risk, only CRP remained a significant predictor of mortality when the inflammation markers were adjusted for one another in multivariable models. Serum CRP levels were a long-term predictor of risk of cardiovascular and non-cardiovascular mortality independent of known risk factors, fibrinogen, and leukocyte count.
Similar content being viewed by others
References
De MM, Franceschi C, Monti D, Ginaldi L. Inflammation markers predicting frailty and mortality in the elderly. Exp Mol Pathol. 2006;80(3):219–27.
De MM, Franceschi C, Monti D, Ginaldi L. Inflamm-ageing and lifelong antigenic load as major determinants of ageing rate and longevity. FEBS Lett. 2005;579(10):2035–9.
Agrawal A. CRP after 2004. Mol Immunol. 2005;42(8):927–30.
Kaptoge S, Di AE, Lowe G, Pepys MB, Thompson SG, Collins R, Danesh J. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375(9709):132–40.
Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350(14):1387–97.
Koenig W, Khuseyinova N, Baumert J, Thorand B, Loewel H, Chambless L, et al. Increased concentrations of C-reactive protein and IL-6 but not IL-18 are independently associated with incident coronary events in middle-aged men and women: results from the MONICA/KORA Augsburg case-cohort study, 1984–2002. Arterioscler Thromb Vasc Biol. 2006;26(12):2745–51.
Il’yasova D, Colbert LH, Harris TB, Newman AB, Bauer DC, Satterfield S, Kritchevsky SB. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev. 2005;14(10):2413–8.
Siemes C, Visser LE, Coebergh JW, Splinter TA, Witteman JC, Uitterlinden AG, et al. C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study. J Clin Oncol. 2006;24(33):5216–22.
Heikkila K, Harris R, Lowe G, Rumley A, Yarnell J, Gallacher J, et al. Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. Cancer Causes Control. 2009;20(1):15–26.
Lee CC, Adler AI, Sandhu MS, Sharp SJ, Forouhi NG, Erqou S, et al. Association of C-reactive protein with type 2 diabetes: prospective analysis and meta-analysis. Diabetologia. 2009;52(6):1040–7.
Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing hypertension. JAMA. 2003;290(22):2945–51.
van Durme YM, Verhamme KM, Aarnoudse AJ, Van Pottelberge GR, Hofman A, Witteman JC, et al. C-reactive protein levels, haplotypes, and the risk of incident chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;179(5):375–82.
Arcari A, Zito F, Di CA, De CA, Dirckx C, Arnout J, et al. C reactive protein and its determinants in healthy men and women from European regions at different risk of coronary disease: the IMMIDIET Project. J Thromb Haemost. 2008;6(3):436–43.
Thorand B, Baumert J, Doring A, Herder C, Kolb H, Rathmann W, et al. Sex differences in the relation of body composition to markers of inflammation. Atherosclerosis. 2006;184(1):216–24.
Festa A, D’Agostino R Jr, Williams K, Karter AJ, Mayer-Davis EJ, Tracy RP, Haffner SM. The relation of body fat mass and distribution to markers of chronic inflammation. Int J Obes Relat Metab Disord. 2001;25(10):1407–15.
Rana JS, Arsenault BJ, Despres JP, Cote M, Talmud PJ, Ninio E, et al. Inflammatory biomarkers, physical activity, waist circumference, and risk of future coronary heart disease in healthy men and women. Eur Heart J. 2011;32(3):336–44.
Huang ZS, Chien KL, Yang CY, Tsai KS, Wang CH. Peripheral differential leukocyte counts in humans vary with hyperlipidemia, smoking, and body mass index. Lipids. 2001;36(3):237–45.
Ruggiero C, Metter EJ, Cherubini A, Maggio M, Sen R, Najjar SS, et al. White blood cell count and mortality in the Baltimore Longitudinal Study of Aging. J Am Coll Cardiol. 2007;49(18):1841–50.
Ford ES, Giles WH, Mokdad AH, Myers GL. Distribution and correlates of C-reactive protein concentrations among adult US women. Clin Chem. 2004;50(3):574–81.
Sinha S, Luben RN, Welch A, Bingham S, Wareham NJ, Day NE, Khaw KT. Fibrinogen and cigarette smoking in men and women in the European prospective investigation into cancer in Norfolk (EPIC-Norfolk) population. Eur J Cardiovasc Prev Rehabil. 2005;12(2):144–50.
Kasapis C, Thompson PD. The effects of physical activity on serum C-reactive protein and inflammatory markers: a systematic review. J Am Coll Cardiol. 2005;45(10):1563–9.
Myint PK, Luben RN, Wareham NJ, Welch AA, Bingham SA, Khaw KT. Physical activity and fibrinogen concentrations in 23,201 men and women in the EPIC-Norfolk population-based study. Atherosclerosis. 2008;198(2):419–25.
Sprague BL, Trentham-Dietz A, Klein BE, Klein R, Cruickshanks KJ, Lee KE, Hampton JM. Physical activity, white blood cell count, and lung cancer risk in a prospective cohort study. Cancer Epidemiol Biomarkers Prev. 2008;17(10):2714–22.
Piche ME, Lemieux S, Weisnagel SJ, Corneau L, Nadeau A, Bergeron J. Relation of high-sensitivity C-reactive protein, interleukin-6, tumor necrosis factor-alpha, and fibrinogen to abdominal adipose tissue, blood pressure, and cholesterol and triglyceride levels in healthy postmenopausal women. Am J Cardiol. 2005;96(1):92–7.
Orakzai RH, Orakzai SH, Nasir K, Santos RD, Rana JS, Pimentel I, et al. Association of white blood cell count with systolic blood pressure within the normotensive range. J Hum Hypertens. 2006;20(5):341–7.
Danesh J, Lewington S, Thompson SG, Lowe GD, Collins R, Kostis JB, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA. 2005;294(14):1799–809.
Kaptoge S, White IR, Thompson SG, Wood AM, Lewington S, Lowe GD, Danesh J. Associations of plasma fibrinogen levels with established cardiovascular disease risk factors, inflammatory markers, and other characteristics: individual participant meta-analysis of 154,211 adults in 31 prospective studies: the fibrinogen studies collaboration. Am J Epidemiol. 2007;166(8):867–79.
Koenig W, Khuseyinova N, Baumert J, Meisinger C. Prospective study of high-sensitivity C-reactive protein as a determinant of mortality: results from the MONICA/KORA Augsburg Cohort Study, 1984–1998. Clin Chem. 2008;54(2):335–42.
Zacho J, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive protein and all-cause mortality—the Copenhagen City Heart Study. Eur Heart J. 2010;31(13):1624–32.
Arima H, Kubo M, Yonemoto K, Doi Y, Ninomiya T, Tanizaki Y, et al. High-sensitivity C-reactive protein and coronary heart disease in a general population of Japanese: the Hisayama study. Arterioscler Thromb Vasc Biol. 2008;28(7):1385–91.
Tuomisto K, Jousilahti P, Sundvall J, Pajunen P, Salomaa V. C-reactive protein, interleukin-6 and tumor necrosis factor alpha as predictors of incident coronary and cardiovascular events and total mortality. A population-based, prospective study. Thromb Haemost. 2006;95(3):511–8.
Tamakoshi K, Toyoshima H, Yatsuya H, Matsushita K, Okamura T, Hayakawa T, et al. White blood cell count and risk of all-cause and cardiovascular mortality in nationwide sample of Japanese–results from the NIPPON DATA90. Circ J. 2007;71(4):479–85.
Day N, Oakes S, Luben R, Khaw KT, Bingham S, Welch A, Wareham N. EPIC-Norfolk: study design and characteristics of the cohort. European prospective investigation of cancer. Br J Cancer. 1999;80(Suppl 1):95–103.
Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA. 1998;279(18):1477–82.
Danesh J, Pepys MB. C-reactive protein and coronary disease: is there a causal link? Circulation. 2009;120(21):2036–9.
Goto M. Inflammaging (inflammation + aging): a driving force for human aging based on an evolutionarily antagonistic pleiotropy theory? Biosci Trends. 2008;2(6):218–30.
Franceschi C, Bonafe M, Valensin S. Human immunosenescence: the prevailing of innate immunity, the failing of clonotypic immunity, and the filling of immunological space. Vaccine. 2000;18(16):1717–20.
Kravitz BA, Corrada MM, Kawas CH. Elevated C-reactive protein levels are associated with prevalent dementia in the oldest-old. Alzheimers Dement. 2009;5(4):318–23.
He LP, Tang XY, Ling WH, Chen WQ, Chen YM. Early C-reactive protein in the prediction of long-term outcomes after acute coronary syndromes: a meta-analysis of longitudinal studies. Heart. 2010;96(5):339–46.
Ormstad H, Aass HC, Lund-Sorensen N, Amthor KF, Sandvik L. Serum levels of cytokines and C-reactive protein in acute ischemic stroke patients, and their relationship to stroke lateralization, type, and infarct volume. J Neurol. 2011;258(4):677–85.
Wang CS, Sun CF. C-reactive protein and malignancy: clinico-pathological association and therapeutic implication. Chang Gung Med J. 2009;32(5):471–82.
Dahl M, Vestbo J, Lange P, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175(3):250–5.
Wensley F, Gao P, Burgess S, Kaptoge S, Di AE, Shah T, et al. Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. BMJ. 2011;342:d548. doi:10.1136/bmj.d548:d548.
Allin KH, Nordestgaard BG, Zacho J, Tybjaerg-Hansen A, Bojesen SE. C-reactive protein and the risk of cancer: a mendelian randomization study. J Natl Cancer Inst. 2010;102(3):202–6.
Chakrabarti S, Lekontseva O, Davidge ST. Estrogen is a modulator of vascular inflammation. IUBMB Life. 2008;60(6):376–82.
Vegeto E, Benedusi V, Maggi A. Estrogen anti-inflammatory activity in brain: a therapeutic opportunity for menopause and neurodegenerative diseases. Front Neuroendocrinol. 2008;29(4):507–19.
Gilliver SC. Sex steroids as inflammatory regulators. J Steroid Biochem Mol Biol. 2010;120(2–3):105–15.
Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura K, et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med. 2004;351(25):2599–610.
Sezer OK, Erenus M, Yoldemir T. The impact of tibolone and hormone therapy on serum C-reactive protein, tumor necrosis factor-alpha and hepatocyte growth factor in postmenopausal women. Climacteric. 2009;12(1):66–71.
Nilsson TK, Boman K, Jansson JH, Thogersen AM, Berggren M, Broberg A, Granlund A. Comparison of soluble thrombomodulin, von Willebrand factor, tPA/PAI-1 complex, and high-sensitivity CRP concentrations in serum, EDTA plasma, citrated plasma, and acidified citrated plasma (Stabilyte) stored at −70 degrees C for 8–11 years. Thromb Res. 2005;116(3):249–54.
Alesci S, Borggrefe M, Dempfle CE. Effect of freezing method and storage at −20 degrees C and −70 degrees C on prothrombin time, aPTT and plasma fibrinogen levels. Thromb Res. 2009;124(1):121–6.
Acknowledgments
We thank all study participants, general practitioners and the EPIC-Norfolk study team for their contribution. The EPIC-Norfolk study is supported by funding from the Medical Research Council and Cancer Research UK with additional support from the Stroke Association, British Heart Foundation, Research into Ageing, and the Academy of Medical Science. S.A. is supported by the Gates Cambridge scholarship. Funding sources did not have a role in the design and conduct of the study, the collection, management, analysis, and interpretation of the data or the preparation, review, approval, or decision to submit the manuscript. S.A. analysed the data and wrote the manuscript with co-authors. R.L. performed all data management and record linkage. KTK and NJW are principal investigators in the EPIC-Norfolk population study. All authors provided detailed comments on the manuscript, reviewed and edited the manuscript and contributed to the discussion.
Conflict of interest
The authors declare that there is no conflict of interest associated with this manuscript.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Ahmadi-Abhari, S., Luben, R.N., Wareham, N.J. et al. Seventeen year risk of all-cause and cause-specific mortality associated with C-reactive protein, fibrinogen and leukocyte count in men and women: the EPIC-Norfolk study. Eur J Epidemiol 28, 541–550 (2013). https://doi.org/10.1007/s10654-013-9819-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10654-013-9819-6